Sofia Khaira brings a wealth of experience in diversity, equity, and inclusion to the table, focusing on how hidden health challenges impact corporate equity and talent management. As an expert in fostering inclusive environments, she understands that menopause is no longer just a private health matter but a critical business priority that affects the highest levels of leadership. Our conversation explores how the “change of life” intersects with professional peak performance and why companies can no longer afford to stay silent about a transition that affects half of the workforce. We delve into the staggering economic fallout of untreated symptoms, the current disconnect between employee demand and employer supply, and the legislative wave that is finally forcing a shift in how human resources departments approach women’s health.
How do menopause symptoms like brain fog and insomnia specifically impact women who are at the height of their leadership careers?
When we look at women in leadership, we are often talking about individuals at the very peak of their earnings and leadership potential. It is a cruel timing of biology that symptoms like hot flashes, trouble sleeping, and forgetfulness tend to hit exactly when these professionals are expected to perform at their most intense levels. This gap in support and treatment has profound economic consequences, contributing to a staggering $1.8 billion in lost work time annually in the United States alone. If a senior leader is struggling to concentrate or facing extreme fatigue due to insomnia, it shouldn’t be seen as a personal failing, yet many are forced to step off the employment curve entirely. We have to realize that when we fail to provide the necessary support, we aren’t just losing an employee; we are losing the accumulated expertise and wisdom of our most seasoned talent.
Despite the clear need for support, many employers seem hesitant to offer specific menopause benefits; what is causing this disconnect?
There is a significant “missed opportunity” here because, while employees are actively demanding these benefits, the supply from the corporate side is almost non-existent. Recent data shows that only 10% of employers currently provide menopause-related accommodations, such as flexible hours or specialty health programs like hormone therapy. Even more concerning is that out of nearly 800 organizations surveyed, 62% admitted they are unlikely to offer menopause leave within the next five years. This disconnect stems from a long-standing stigma that frames menopause as a niche or private issue rather than a standard part of the aging process. Employers are essentially waiting on the sidelines while their workforce struggles, failing to see that innovation in this space is the next frontier for gender-equitable benefits.
In what ways are external factors, like changes in federal health guidelines and new state laws, beginning to reshape the corporate conversation?
The landscape is shifting rapidly because the medical and legal frameworks that once restricted support are finally evolving. For years, hormone replacement therapy was surrounded by fear, but the FDA recently removed the “black box” warning label from six menopausal hormone products, which fundamentally opened up a new world of treatment alternatives. On the legislative front, we are seeing a groundswell of activity, starting with Rhode Island, which became the first state to mandate workplace accommodations for menopause as of June 24, 2025. Other major states like California, New York, and Virginia are following suit with their own proposals to bridge this gap in anti-discrimination laws. This trend is effectively making implicit expectations explicit, forcing companies to integrate menopause into their existing compliance and health structures.
How should businesses view menopause support as a strategic tool for talent retention rather than just a compliance issue?
Retention is the most immediate risk for companies that ignore this transition, as evidenced by the fact that 13% of 8,000 women surveyed globally have actually quit their jobs due to symptoms. Another 15% have seriously considered leaving, which represents a massive drain on the talent pipeline that businesses simply cannot afford. When 7 in 10 U.S. adults agree that women should not be expected to silently “push through” these symptoms, it signals a massive shift in cultural expectations that HR must meet. By offering simple accommodations like health programs, hormone therapy coverage, or extra time off, a company differentiates itself as an employer of choice. It is about creating an environment where a woman doesn’t feel she has to choose between her health and her career longevity.
What is your forecast for menopause support in the workplace over the next decade?
I anticipate that the next ten years will see a total normalization of menopause support, transforming it from a “specialty benefit” into a standard pillar of any comprehensive health package. As more states pass legislation similar to Rhode Island’s groundbreaking law, the legal pressure will combine with the removal of medical stigmas to make these benefits a baseline requirement. We will see the 62% of hesitant employers gradually shrink as they realize that the $1.8 billion in lost productivity is a cost they can mitigate through proactive care. Ultimately, the goal is to eliminate the silence surrounding this life stage so that senior leaders can remain at the helm of their organizations while being their best selves at work. My forecast is that menopause will soon be handled with the same transparency and support as maternity leave or any other major health milestone.
